CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia

Show full item record



Permalink

http://hdl.handle.net/10138/321623

Citation

Cuesta-Mateos , C , Fuentes , P , Schrader , A , Juarez-Sanchez , R , Loscertales , J , Mateu-Albero , T , Vega-Piris , L , Espartero-Santos , M , Marcos-Jimenez , A , Sanchez-Lopez , B A , Perez-Garcia , Y , Jungherz , D , Oberbeck , S , Wahnschaffe , L , Kreutzman , A , Andersson , E I , Mustjoki , S , Faber , E , Urzainqui , A , Fresno , M , Stamatakis , K , Alfranca , A , Terron , F , Herling , M , Toribio , M L & Munoz-Calleja , C 2020 , ' CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia ' , Biomarker Research , vol. 8 , no. 1 , 54 . https://doi.org/10.1186/s40364-020-00234-z

Title: CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia
Author: Cuesta-Mateos, Carlo; Fuentes, Patricia; Schrader, Alexandra; Juarez-Sanchez, Raquel; Loscertales, Javier; Mateu-Albero, Tamara; Vega-Piris, Lorena; Espartero-Santos, Marina; Marcos-Jimenez, Ana; Sanchez-Lopez, Blanca Andrea; Perez-Garcia, Yaiza; Jungherz, Dennis; Oberbeck, Sebastian; Wahnschaffe, Linus; Kreutzman, Anna; Andersson, Emma I.; Mustjoki, Satu; Faber, Edgar; Urzainqui, Ana; Fresno, Manuel; Stamatakis, Kostantino; Alfranca, Arantzazu; Terron, Fernando; Herling, Marco; Toribio, Maria Luisa; Munoz-Calleja, Cecilia
Contributor: University of Helsinki, HUSLAB
University of Helsinki, HUS Comprehensive Cancer Center
Date: 2020-10-24
Language: eng
Number of pages: 17
Belongs to series: Biomarker Research
ISSN: 2050-7771
URI: http://hdl.handle.net/10138/321623
Abstract: T-cell prolymphocytic leukemia (T-PLL) is a poor prognostic disease with very limited options of efficient therapies. Most patients are refractory to chemotherapies and despite high response rates after alemtuzumab, virtually all patients relapse. Therefore, there is an unmet medical need for novel therapies in T-PLL. As the chemokine receptor CCR7 is a molecule expressed in a wide range of malignancies and relevant in many tumor processes, the present study addressed the biologic role of this receptor in T-PLL. Furthermore, we elucidated the mechanisms of action mediated by an anti-CCR7 monoclonal antibody (mAb) and evaluated whether its anti-tumor activity would warrant development towards clinical applications in T-PLL. Our results demonstrate that CCR7 is a prognostic biomarker for overall survival in T-PLL patients and a functional receptor involved in the migration, invasion, and survival of leukemic cells. Targeting CCR7 with a mAb inhibited ligand-mediated signaling pathways and induced tumor cell killing in primary samples. In addition, directing antibodies against CCR7 was highly effective in T-cell leukemia xenograft models. Together, these findings make CCR7 an attractive molecule for novel mAb-based therapeutic applications in T-PLL, a disease where recent drug screen efforts and studies addressing new compounds have focused on chemotherapy or small molecules.
Subject: CCR7
T-PLL
mAb
T-cell lymphomas
Immunotherapy
CHRONIC LYMPHOCYTIC-LEUKEMIA
CHEMOKINE RECEPTORS
EXPRESSION
ALEMTUZUMAB
INFILTRATION
MIGRATION
KINASE
CD52
SKIN
CHEMOIMMUNOTHERAPY
3111 Biomedicine
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
s40364_020_00234_z.pdf 2.603Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record